VLRX - Valeritas Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Valeritas Holdings, Inc.

750 Route 202 South
Suite 600
Bridgewater, NJ 08807
United States

IndustryMedical Instruments & Supplies
Full Time Employees125

Key Executives

NameTitlePayExercisedYear Born
Mr. John E. TimberlakePres, CEO & Director654.55kN/A1965
Mr. Erick J. Lucera CPA, CFACFO & Sec.408kN/A1968
Mr. Geoffrey H. JenkinsExec. VP of Manufacturing, Operations and R&D328.44kN/A1952
Dr. Matthew H. NguyenChief Commercial Officer410.9kN/A1970
Mr. Joseph SaldanhaChief Bus. Officer349.75kN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Valeritas Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.